ライフサイエンスコーパス: lactam

1 ation of an altrose beta-lactam monomer (alt-lactam).

2 ing group to generate the desired conjugated lactam.

3 ion of cuprate to the alpha,beta-unsaturated lactam.

4 actericidal effect, are not inferior to beta-lactams.

5 les that restore sensitivity of MRSA to beta-lactams.

6 native S. aureus PBPs are inhibited by beta-lactams.

7 n important class of medicinally significant lactams.

8 ce to the carbapenem imipenem and other beta-lactams.

9 ride to transform aliphatic amines into beta-lactams.

10 N-alkylation of the corresponding non-planar lactams.

11 of the highly effective antibacterials, beta-lactams.

12 ed evolved prior to the clinical use of beta-lactams.

13 ains with their inhibition by different beta-lactams.

14 tection ranges were 0.26-3.56 ng/mL for beta-lactams, 0.04-0.98 ng/mL for tetracyclines, 0.08-2.0 ng/

15 eta-lactamases, enzymes that inactivate beta-lactams, a class of antibiotics that has been a therapeu

16 t the full range of MBLs and potentiate beta-lactam activity against producer pathogens.

17 t Enterobacteriaceae and restoration of beta-lactam activity in a broad range of MDR Gram-negative pa

18 beta-lactam allergies to safely promote beta-lactam administration among these patients is warranted.

19 Continuous beta-lactam administration was not independently associated w

20 In a multivariable model, intermittent beta-lactam administration, higher Acute Physiology and Chron

21 st both the dose and dosing interval of beta-lactam agents allows the treatment of strains with eleva

22 Beta-lactam agents have the highest rates of resistance and l

23 h regioselectivity of the oxidation in these lactam alkenes might be due to the participation of the

24 nd the tolerability of such alternative beta-lactams, all subjects underwent skin tests with cephalex

25 rograms aimed at accurately identifying beta-lactam allergies to safely promote beta-lactam administr

26 Predictors of interest were history of beta-lactam allergy and receipt of preferred beta-lactam ther

27 burden and clinical impact of reported beta-lactam allergy on patients seen by infectious diseases c

28 Of 827 patients with reported beta-lactam allergy over 15 months, beta-lactam therapy was p

29 beta-lactam allergy skin testing (BLAST) is recommended by an

30 Among 507 patients, 95 (19%) reported beta-lactam allergy; preferred therapy was a beta-lactam in 7

31 6/10,215 (1.4%) patients who received a beta-lactam alone (crude RR 0.61, 95% CI 0.45, 0.83).

32 e versus 7,314/52,504 [13.9%] receiving beta-lactam alone).

33 tant to multiple antibiotics, including beta-lactams, aminoglycosides, fluoroquinolones, and polymyxi

34 dy chooses four classes of antibiotics, beta-lactam (ampicillin and penicillin), quinolone (enoxacin)

35 the amide linker resulted in a six-membered lactam analogue, compound 18.

36 ecause combination therapy using both a beta-lactam and a second antibiotic suppressing the small rev

37 -streptogramin, bacitracin, vancomycin, beta-lactam and aminoglycoside resistance genes were the top

38 esistance in Staphylococcus aureus, and beta-lactam and co-trimoxazole resistance in Streptococcus pn

39 ciency potentiates antibiotics from the beta-lactam and quinolone classes.

40 n of the two side chains carried by the beta-lactam and the five-membered rings of the carbapenem cor

41 nicillin N synthase (IPNS) installs the beta-lactam and thiazolidine rings of the penicillin core int

42 ion reaction involving various gamma-hydroxy lactams and C/O/S nucleophiles at room temperature.

43 ons were lower than those observed with beta-lactams and close to those observed with amikacin.

44 ibition of MBLs by beta-lactams and non-beta-lactams and illustrate the utility of PrOF NMR for effic

45 he mechanisms and inhibition of MBLs by beta-lactams and non-beta-lactams and illustrate the utility

46 between beta-arylated alpha-methylidene-beta-lactams and terminal olefins was developed.

47 her single agent alone (vancomycin or a beta-lactam) and SSI was evaluated.

48 The imine, unsaturated lactam, and cyclopropane are essential for efficient DNA

49 ntibiotic treatment was primarily using beta-lactams, and 37% of patients received rifampin.

50 pharmacologically relevant carbazoles, delta-lactams, and oxindole derivatives).

51 nspeptidase domain is a major target of beta-lactams, and therefore it is important to attain a detai

52 The mechanism of the beta-lactam antibacterials is the functionally irreversible a

53 effectively inhibit PrkA and potentiate beta-lactam antibiotic activity to varying degrees.

54 n synaptic contact were reversed by the beta-lactam antibiotic ceftriaxone.

55 acA mutants are highly sensitive to the beta-lactam antibiotic cefuroxime.

56 vancomycin plus 1 other antipseudomonal beta-lactam antibiotic combination (adjusted odds ratio, 3.40

57 Optimization of beta-lactam antibiotic dosing for critically ill patients is

58 ditions of induction of resistance to a beta-lactam antibiotic identified two signaling muropeptides

59 introduction of this second generation beta-lactam antibiotic into clinical practice.

60 active process and was inhibited by the beta-lactam antibiotic oxacillin, which slowed inactivation o

61 and hypersensitive patients taking the beta-lactam antibiotic piperacillin and the threshold require

62 new user of an oral fluoroquinolone or beta-lactam antibiotic prescription with at least 24 months o

63 The beta-lactam antibiotic temocillin (6-alpha-methoxy-ticarcilli

64 y with vancomycin and 1 antipseudomonal beta-lactam antibiotic throughout the first week of hospitali

65 strate that bacterial persisters, under beta-lactam antibiotic treatment, show less cytoplasmic drug

66 turbance, severe neutropenia, and prior beta-lactam antibiotic use.

67 vancomycin plus 1 other antipseudomonal beta-lactam antibiotic, 157 patients (8.2%) had antibiotic-as

68 of beta-lactamase in the absence of any beta-lactam antibiotic, thus indicating that they serve as ch

69 vancomycin plus 1 other antipseudomonal beta-lactam antibiotic.

70 ) compared with vancomycin plus 1 other beta-lactam antibiotic.

71 presence of other structurally related beta-lactam antibiotics (amoxicillin, oxacillin, penicillin G

72 Resistance of S. aureus strains to beta-lactam antibiotics (eg, oxacillin) depends on the produc

73 in bacterial mechanism of resistance to beta-lactam antibiotics and are a significant challenge to mo

74 -lactamases (MBLs) hydrolyze almost all beta-lactam antibiotics and are unaffected by clinically avai

75 tamases catalyze the hydrolysis of most beta-lactam antibiotics and hence represent a major clinical

76 beta-Lactamases (BLs) able to hydrolyze beta-lactam antibiotics and more importantly the last resort

77 The targets of beta-lactam antibiotics are bacterial DD-peptidases that cata

78 beta-Lactam antibiotics are often coadministered with intrave

79 a effectively discriminates against the beta-lactam antibiotics as potential inhibitors, and in favor

80 intermittent dosing, administration of beta-lactam antibiotics by continuous infusion in critically

81 omplex crystal structures of KPC-2 with beta-lactam antibiotics containing hydrolyzed cefotaxime and

82 nterobacteriaceae are resistant to most beta-lactam antibiotics due to the production of the Klebsiel

83 d that reversed intrinsic resistance to beta-lactam antibiotics in a manner distinct from beta-lactam

84 s are enzymes that confer resistance to beta-lactam antibiotics in bacteria, and there is a critical

85 tinuous versus intermittent infusion of beta-lactam antibiotics in critically ill patients with sever

86 e pauA2 mutant became more sensitive to beta-lactam antibiotics in human serum.

87 and the manifestation of resistance to beta-lactam antibiotics in many Enterobacteriaceae and Pseudo

88 Reported allergy to beta-lactam antibiotics is common and often leads to unnecess

89 The target of beta-lactam antibiotics is the D,D-transpeptidase activity of

90 The efficacy of beta-lactam antibiotics is threatened by the emergence and gl

91 Resistance to beta-lactam antibiotics mediated by metallo-beta-lactamases (

92 Our data indicate that beta-lactam antibiotics should be included in the treatment r

93 I) lowered the MIC breakpoints for many beta-lactam antibiotics to enhance detection of known resista

94 tinuous versus intermittent infusion of beta-lactam antibiotics.

95 tamases enable resistance to almost all beta-lactam antibiotics.

96 ese kinases in regulating resistance to beta-lactam antibiotics.

97 of resistance or susceptibility against beta-lactam antibiotics.

98 23S rRNA) associated with resistance to beta-lactam antimicrobials, macrolides, or fluoroquinolones.

99 CI], 1.45-5.42), as was narrow-spectrum beta-lactams (aOR, 3.54; 95% CI, 1.98-6.33), and appropriate

100 mark, we quantified four broad-spectrum beta-lactam AR genes (ARG; bla(TEM), bla(SHV), bla(OXA) and b

101 Allergic reactions to beta-lactams are among the most frequent causes of drug aller

102 However, because beta-lactams are chemical and structural mimics of the natura

103 hanging the removable components and of beta-lactams are confirmed and maybe also a potential benefit

104 taphylococcus aureus (MSSA) infections, beta-lactams are recommended for definitive therapy; however,

105 alpha-quaternary beta-homo prolines and beta-lactams, are also prepared in two- to three-steps from t

106 "Total" beta-lactam ARG levels were significantly higher in M versus

107 hed methods, which usually lead to amides or lactams arising from formal NH insertion as the major pr

108 immediate hypersensitivity reactions to beta-lactams, aspirin, and nonsteroidal anti-inflammatory dru

109 lineate an advantageous approach toward beta-lactams based on a two-step, one-pot protocol: an intram

110 the discovery of compound 4a, a potent beta-lactam-based monoacylglycerol lipase (MGL) inhibitor cha

111 Genes involved in IR to beta-lactams belonged to HLA type 2 antigen processing, IgE p

112 ombined with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a car

113 ications for the use of next-generation beta-lactam-beta-lactamase inhibitor combinations.

114 m and ceftazidime/avibactam are 2 novel beta-lactam/beta-lactamase combination antibiotics.

115 alternative drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bl

116 nt to cephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant st

117 Previous use of beta-lactam/beta-lactamase or carbapenems and recent hospital

118 65 [95% CI, 1.15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95%

119 d-BTZ complexes most closely resemble beta-lactam binding to B1 MBLs, but feature an unprecedented

120 ns (BSIs) in patients presenting with a beta-lactam (BL) allergy is often a difficult decision given

121 (DPT) are commonly performed as part of beta-lactam (BL) allergy workup, in case of negative skin tes

122 d an algorithm for diagnosing immediate beta-lactam (BL) allergy.

123 onverted to free gamma-amino acids and gamma-lactams, both of which are common structural motifs foun

124 By combination of palmitoylation, lactam-bridging, and Nalpha-methylation, ADM analogues p

125 10 linear steps starting from a single delta-lactam building block, is reported.

126 eta-imino lactams that then afford beta-keto lactams by acid hydrolysis.

127 Pneumococcus resists beta-lactams by expressing variants of its target enzymes, th

128 hogen Listeria monocytogenes to various beta-lactams by inhibiting the PASTA kinase PrkA.

129 pping experiments, thus confirming that beta-lactams can be designed that are capable of releasing al

130 A diverse range of polysubstituted beta-lactams can be generated by systematic variation of the

131 on followed by reductive removal of the beta-lactam carbonyl moiety.

132 ar Typhi strain with resistance against beta-lactams, cephalosporins (extended-spectrum beta-lactamas

133 l resistance determinants for different beta-lactams, ciprofloxacin, and tetracyclines on multiple oc

134 vancomycin plus 1 other antipseudomonal beta-lactam combination therapy at 1 of 6 large children's ho

135 s, were used to predict resistance to 4 beta-lactams commonly used in the empiric treatment of neutro

136 es were challenged with the alternative beta-lactams concerned.

137 The synthesis of a small set of beta-lactams containing isocyanate precursors is described.

138 e late-stage functionalization of amide- and lactam-containing drugs, and naturally occurring alkaloi

139 Additional optimization of the lactam-containing EZH2 inhibitors focused on lipophilic

140 A novel series of beta-lactam derivatives that was designed and synthesized to

141 rticle describes the design and synthesis of lactam-derived M1 PAMs that address this hypothesis.

142 phs were noted, one containing the five beta-lactam drugs and the other containing both sulfonamides,

143 ticularly plasmid-encoded resistance to beta lactam drugs, poses an increasing threat to human health

144 , and long treatments (>/=21 days) with beta-lactams, either as monotherapy (0.48) or in combination

145 Ni-catalyzed three-component coupling of lactam enolates, benzonitriles, and aryl halides produce

146 laNDM-1, and selected extended-spectrum beta-lactam (ESBL) resistant bacteria and genes in 12 hospita

147 losporins, which are antibiotics in the beta-lactam family that target cell-wall biosynthesis.

148 vation of a readily available C21-oxygenated lactam, followed by transannular cyclization and in situ

149 roxyalkyl azide with a ketone, which affords lactams following nucleophilic opening of initially form

150 on of vancomycin and antistaphylococcal beta-lactams for methicillin-resistant Staphylococcus aureus

151 The use of non-carbapenem beta-lactams for the treatment of ESBL infections has yielded

152 : Prolonged infusion of antipseudomonal beta-lactams for the treatment of patients with sepsis was as

153 (</=60 min) infusion of antipseudomonal beta-lactams for the treatment of patients with sepsis was el

154 ticomponent method for the synthesis of beta-lactams from imines, aryl halides, and CO has been devel

155 ly chemoselective reduction of the amide and lactam functionalities using IrCl(CO)[P(C6 H5 )3 ]2 (Vas

156 pertoire that can be activated with the beta-lactam hapten and/or an imbalance in immune regulation.

157 s, even when in vitro activity to other beta-lactams has been demonstrated.

158 While beta-lactams have a relatively slow effect, both tested phage

159 ups of enzymes, their substrates and of beta-lactams have led to the conclusion that beta-lactamases

160 beta-lactamases, enzymes that catalyze beta-lactam hydrolysis.

161 Delayed-type beta-lactam hypersensitivity develops in subset of patients.

162 beta-Lactam hypersensitivity has been classified according to

163 y was to use piperacillin as a model of beta-lactam hypersensitivity to study the nature of the drug-

164 T cells are detectable in patients with beta-lactam hypersensitivity.

165 lactam allergy; preferred therapy was a beta-lactam in 72 (76%).

166 ime) complexes with PBP2a-each with the beta-lactam in the allosteric site-defined (with preceding PB

167 tforms for detecting resistance against beta-lactams in 72 highly resistant isolates of Escherichia c

168 to the formation of trans-disubstituted beta-lactams in excellent yields and selectivities.

169 orresponding alpha-alkylidene-beta-aryl-beta-lactams in good isolated yields (41-83%) with exclusive

170 ted imines to produce novel spirocyclic beta-lactams in good yields and selectivity.

171 short-term infusion of antipseudomonal beta-lactams in patients with sepsis.

172 intravenous infusion of antipseudomonal beta-lactams in patients with sepsis.

173 coli PBP1b bound to multiple different beta-lactams in the transpeptidase active site and complement

174 alpha-substituted lactams to form beta-keto lactams in up to 94% ee.

175 egarding the effectiveness of prolonged beta-lactam infusion.

176 the direct incorporation of monocyclic beta-lactams into a variety of molecular architectures.

177 Bacterial resistance to beta-lactams is achieved by the production of beta-lactamases

178 c and aliphatic tertiary amides, and N-alkyl lactams is reported.

179 amines to their corresponding 3-alkoxyamine lactams is reported.

180 comparative effectiveness of individual beta-lactams is unknown.

181 ion, and high yields (78-89%) of the desired lactam ketones are obtained.

182 ene generation-C-H insertion reaction of the lactam ketones revealed that the reaction efficiency is

183 o mecA, mecC confers resistance against beta-lactams, leading to the phenotype of methicillin-resista

184 eoxysugar, and antibiotics derived from beta-lactams, macrolides, and aminocoumarins.

185 te-to-active site communication and for beta-lactam mimicry of the peptidoglycan substrates, as found

186 molecule with imbedded biphenyl, amine, and lactam moieties, 7,8-diallyl-5-benzyl-7,8-dihydrodibenzo

187 ng-opening polymerization of an altrose beta-lactam monomer (alt-lactam).

188 = 1737) demonstrated noninferiority of beta-lactam monotherapy (n = 506) vs beta-lactam plus macroli

189 the study period; 1019 (71.9%) received beta-lactam monotherapy and 399 (28.1%) received beta-lactam

190 beta-Lactam monotherapy and beta-lactam plus macrolide combin

191 ospital stay between children receiving beta-lactam monotherapy and combination therapy (median, 55 v

192 ation therapy conferred no benefit over beta-lactam monotherapy for children hospitalized with commun

193 ycoside combination therapy compared to beta lactam monotherapy in patients with sepsis.

194 ly confirmed pneumonia and who received beta-lactam monotherapy or beta-lactam plus macrolide combina

195 To compare the effectiveness of beta-lactam monotherapy vs beta-lactam plus macrolide combina

196 failed to demonstrate noninferiority of beta-lactam monotherapy vs beta-lactam plus macrolide combina

197 We defined the referent as beta-lactam monotherapy, including exclusive use of an oral o

198 % to 5.2%) in 90-day mortality favoring beta-lactam monotherapy.

199 f 30% to 43% in mortality compared with beta-lactam monotherapy.

200 Beta-lactam, multidrug efflux pumps, fluoroquinolone, and ant

201 rminants of immediate reactions (IR) to beta-lactams (n = 19), NAR against aspirin (n = 12) and other

202 lergy who received either a BL or a non-beta-lactam (NBL).

203 nes might be due to the participation of the lactam nitrogen via intramolecular coordination to Pd(II

204 nfluenced strongly by the side chains on the lactam nitrogen.

205 nd secrete the antibiotic penicillin, a beta-lactam nonribosomal peptide, by taking genes from a fila

206 oline ring yielded an optically active gamma-lactam of protected alpha-quaternary serine derivative.

207 putative instances of resistance to the beta-lactams of interest identified by WGS, only 87 (65%) wou

208 Combinations of beta-lactams of the carbapenem class, such as meropenem, with

209 In all, 70,101 procedures (52,504 beta-lactam only, 5,089 vancomycin only, and 12,508 combinati

210 "top" ring to form an alpha,beta-unsaturated lactam or an alpha,beta-unsaturated sultam.

211 The crystal structures of three beta-lactams (oxacillin, cefepime, ceftazidime) complexes wit

212 unique mercaptolactated gamma-pyranol-gamma-lactams, paraphaeosphaerides E-H (1-4) together with one

213 led to demonstrate clinical benefits of beta lactam plus aminoglycoside combination therapy compared

214 Use of a beta-lactam plus an oral or parenteral macrolide (azithromyci

215 of beta-lactam monotherapy (n = 506) vs beta-lactam plus macrolide combination therapy (n = 566), wit

216 ctiveness of beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy among a cohort

217 beta-Lactam monotherapy and beta-lactam plus macrolide combination therapy are both commo

218 monia, antibiotic therapy consisting of beta-lactam plus macrolide combination therapy or fluoroquino

219 pulations of 1188 to 24,780) found that beta-lactam plus macrolide combination therapy was associated

220 feriority of beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy, with an absol

221 al stability on hospital day 7 favoring beta-lactam plus macrolide combination therapy.

222 who received beta-lactam monotherapy or beta-lactam plus macrolide combination therapy.

223 am monotherapy and 399 (28.1%) received beta-lactam plus macrolide combination therapy.

224 Use of combination prophylaxis with a beta-lactam plus vancomycin is increasing; however, the relat

225 ections and confirm that aztreonam-like beta-lactams plus nonclassical beta-lactamase inhibitors, par

226 oquinolone prescription compared with a beta-lactam prescription using multivariate regression with C

227 chloride initiated polymerization of the alt-lactam proceeds smoothly to afford stereoregular polymer

228 nding of both inhibitors and hydrolyzed beta-lactam products to SPM-1.

229 portant in securing good yields for the beta-lactam products.

230 cyclopentenone, and a highly chemoselective lactam reduction delivered the natural product target.

231 beta-Lactams represent one of the most important classes of a

232 inkage between specific determinants of beta-lactam resistance (e.g. beta-lactamase) and redox potent

233 to antibiotic resistance; for example, beta-lactam resistance by L,D-transpeptidase activities.

234 ction regulates gene expression for the beta-lactam resistance enzyme, beta-lactamase.

235 ed for identification of PBP2a-mediated beta-lactam resistance in human and animal clinical isolates

236 as screened for the ability to suppress beta-lactam resistance in Mycobacterium smegmatis.

237 oratory testing to detect mecC-mediated beta-lactam resistance in Staphylococcus aureus Kriegeskorte

238 e viability, the PAD was used to detect beta-lactam resistance in wastewater and sewage and identifie

239 , detoxification and aminoglycoside and beta-lactam resistance.

240 from antibiotic tolerance to high-level beta-lactam resistance.

241 activity of PBPs and to broad-spectrum beta-lactam resistance.

242 amics of the Sao Paulo MBL (SPM-1) from beta-lactam-resistant Pseudomonas aeruginosa.

243 and imines provides gamma-butyrolactones and lactams, respectively.

244 preinstalling the beta configuration of the lactam ring in the monomer via the stereospecific [2+2]

245 lly compatible with the highly unstable beta-lactam ring of carbapenems and that the triazole ring ge

246 800CW, with a quencher connected through the lactam ring that is hydrolyzed by the enzyme BlaC (beta-

247 o-S-CCys,beta-H bond for closure of the beta-lactam ring, and the CVal,beta-H bond for installation o

248 uaternary stereocenter at C3 position of the lactam ring, can act as effective reverse-turn mimics an

249 e featuring non-canonical lactone as well as lactam rings.

250 Nonetheless, beta-lactams showed mycobactericidal activity in combination

251 cultures establish that modification of the lactam side chain of the 7-azaindenoisoquinolines can mo

252 n these enzymes' active site structure, beta-lactam specificity and metal content.Carbapenem-resistan

253 igh yields (53-76%) of both gamma- and delta-lactam spirocycles were obtained.

254 The impact of lactam stapling was found to vary strongly with regard t

255 nder the reaction conditions, including beta-lactam-, steroid-, and sugar-derived ones, leading to de

256 of amino acids that interact with bound beta-lactam substrates.

257 hanistic aspects of how Mtb responds to beta-lactams such as Amoxicillin in combination with Clav (re

258 the widespread use of first generation beta-lactams such as penicillin in the years prior to the int

259 n and increases antibiotic tolerance to beta-lactams, suggesting that HQNO-dependent cell autolysis i

260 tes facilitated syntheses of monocyclic beta-lactams suitable for incorporation of a thiomethyl and e

261 n accommodate additional substituents on the lactam/sultam ring and allows late stage sequential func

262 ased time-kill assays show BTZs restore beta-lactam susceptibility of Escherichia coli-producing MBLs

263 timized for inactivation of the unusual beta-lactam targets of Mycobacterium tuberculosis or for esca

264 itative analysis, the cut-off values of beta-lactams, tetracyclines, quinolones and sulfonamides were

265 ection of four families of antibiotics (beta-lactams, tetracyclines, quinolones and sulfonamides) in

266 od provides rapid access to a broad range of lactams that are widely useful building blocks in alkalo

267 triles, and aryl halides produces beta-imino lactams that then afford beta-keto lactams by acid hydro

268 old greater odds of receiving preferred beta-lactam therapy (95% confidence interval, 2.4-8.2; P < .0

269 riods, 50% (124/246) received preferred beta-lactam therapy based on history, compared with 60% (232/

270 ntrast, patients who received preferred beta-lactam therapy had a similar risk of adverse events comp

271 RMD platforms can help inform empiric beta-lactam therapy in cases where bla genes are not detected

272 Avoidance of preferred beta-lactam therapy in patients who report allergy is associa

273 ted beta-lactam allergy over 15 months, beta-lactam therapy was preferred among 632 (76%).

274 When beta-lactam therapy was preferred, 25 (35%) did not receive p

275 Ps resulted in greater use of preferred beta-lactam therapy without increasing the risk of adverse dr

276 lactam allergy and receipt of preferred beta-lactam therapy.

277 m should be considered when determining beta-lactam therapy.

278 ion of patients receiving the preferred beta-lactam therapy.

279 beneficial as treatments adjunctive to beta-lactam therapy.

280 e reaction sequence involves conversion of a lactam to a thioiminium ion followed by reaction with an

281 ple procedure for the conversion of tertiary lactams to 2-monoalkylated cyclic amines is described.

282 uaternary stereocenters on alpha-substituted lactams to form beta-keto lactams in up to 94% ee.

283 r the alpha,beta-desaturation of N-protected lactams to their conjugated unsaturated counterparts und

284 tramolecular Alder-ene (IMAE) reaction and a lactam-to-lactone rearrangement of tetracycle 13, a comp

285 e present an operationally simple lactone-to-lactam transformation utilizing diverse amine nucleophil

286 jority of cases were treated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

287 e variety of amides (primary, secondary) and lactams under operationally simple conditions without th

288 of 2 antimicrobials (vancomycin plus a beta-lactam) versus either single agent alone (vancomycin or

289 values produced highly functionalized gamma-lactams via a 5-endo-trig radical-polar crossover proces

290 unctionality from stable indole-linked delta-lactams via a highly chemoselective iridium(I)-catalyzed

291 he synthesis of substituted gamma- and delta-lactams via palladium-catalyzed alkene carboamination re

292 The preparation of unsaturated secondary lactams via the palladium-catalyzed cyclization of O-phe

293 action during O-alkylation of a beta-hydroxy lactam was found to be highly dependent on the temperatu

294 lone and 3,543,797 patients receiving a beta-lactam were included in the analysis.

295 Enantiopure 4-formyl-beta-lactams were deployed as synthons for the diastereoselec

296 Whereas beta-lactams were responsible for strong cell morphology chan

297 -lactamase can catalyze hydrolysis of a beta-lactam while that of a DD-peptidase cannot?

298 Combining an antistaphylococcal beta-lactam with vancomycin may shorten the duration of MRSA

299 ndergo formal [4+2] cycloaddition to provide lactams with high levels of enantio- and diastereoselect

300 Lactams with various ring sizes and substituents at diff